secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2022-08-03T23:59:59+00:00
Accession:  0000950170-22-014242
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology Q2 net loss $34.8M; identifies ziftomenib Phase 2 dose, $450M cash runway through 2024
--------------------------------------------------------------------------------

- Net loss of $34.8M in Q2 2022 vs. $33.7M in Q2 2021; R&D expenses rose to $24.3M.
- Cash, cash equivalents and investments total $450.3M as of June 30, 2022, providing runway through 2024.
- Recommended Phase 2 dose for ziftomenib identified, pending FDA review; additional 18 patients enrolled in KOMET-001 trial.
- Preliminary activity observed in KURRENT-HN trial of tipifarnib + alpelisib; first patient dosed in HRAS overexpression cohort.
- KURRENT-LUNG trial of tipifarnib + osimertinib to initiate in Q3; IND for KO-2806 expected by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000095017022014242/0000950170-22-014242-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000095017022014242/kura-20220803.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-014242

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer